Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 20/20 | 0.82 |
| ▸ | JAK3 | P52333 | 18/20 | 0.82 |
| ▸ | PTK2 | Q05397 | 17/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3267596 | 0.91 | JAK2 (0.79) | JAK2JAK3PTK2 | |
| SCHEMBL2634224 | 0.90 | JAK2 (1.00) | JAK2JAK3PTK2 | |
| SCHEMBL2634570 | 0.87 | JAK2 (1.00) | JAK2JAK3PTK2 | |
| SCHEMBL15048587 | 0.86 | JAK2 (0.66) | JAK2JAK3PTK2 | |
| SCHEMBL2640275 | 0.83 | JAK2 (1.00) | JAK2JAK3PTK2 | |
| SCHEMBL3216706 | 0.82 | JAK2 (0.83) | JAK2JAK3PTK2 | |
| SCHEMBL1423234 | 0.82 | JAK2 (0.74) | JAK2JAK3PTK2 | |
| SCHEMBL3193443 | 0.82 | JAK2 (0.83) | JAK2JAK3PTK2 | |
| SCHEMBL2634700 | 0.81 | JAK2 (1.00) | JAK2JAK3PTK2 | |
| SCHEMBL13072927 | 0.81 | JAK2 (0.84) | JAK2JAK3PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264747-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | ZHU BING-YAN (US) | 2012-10-18 | — | — | US | disclosed |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264747-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885PTK2 312/4885 |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885PTK2 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.